<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480467</url>
  </required_header>
  <id_info>
    <org_study_id>3182A1-102</org_study_id>
    <nct_id>NCT00480467</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males</brief_title>
  <official_title>Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of ascending single oral doses of SAM-315, an
      investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic
      (PK) and pharmacodynamic (PD) profiles of SAM-315 in healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAM-315</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men aged 20 to 45 years (inclusive) at the time of getting informed consent.

          -  Body mass index (BMI) in the range of 18.5 to 25.0 kg/m2 and body weightâ‰¥50 kg (BMI =
             [weight (kg)]/[height (m)]2).

          -  Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs, and digital 12-lead
             electrocardiogram (ECG). Alanine aminotransferase (ALT), aspartate aminotransferase
             (AST) and creatinine levels must be within the upper limit of normal for eligibility.

        Exclusion criteria

          -  Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

          -  Any clinically important deviation from normal limits in physical examination, vital
             signs, digital 12-lead ECGs, or clinical laboratory test results.

          -  Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or cola)
             or alcoholic beverages is prohibited from 48 hours and consumption of grapefruit or a
             grapefruit-containing products is prohibited from 72 hours before study day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ibaraki Pref</city>
        <zip>305-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

